Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
high-dose methotrexate
primary central nervous system lymphoma
risk factors
toxicity
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
30
07
2022
received:
11
05
2022
accepted:
18
09
2022
pubmed:
20
10
2022
medline:
24
12
2022
entrez:
19
10
2022
Statut:
ppublish
Résumé
Methotrexate (MTX) is an antimetabolic antitumor drug with high individual differences and may lead to severe toxicities in a considerable number of patients. This study aimed to explore the factors influencing major adverse events in patients with primary central nervous system lymphoma treated with high-dose MTX (HD-MTX), which could be useful in clinical practice. Fifty-four patients who received 175 courses of MTX at 3-8 g/m A total of 124 adverse events occurred after MTX infusion. Using independent sample t-tests, we found that patients with myelosuppression had higher MTX area under the concentration-time curve up to 48 h after infusion (AUC Our study demonstrated that co-administration of VDS, eGFR before MTX infusion, and the baseline index of laboratory examinations including ALT, WBC, LDH may be useful biomarkers for predicting MTX-induced toxicities.
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Antimetabolites, Antineoplastic
0
Vindesine
RSA8KO39WH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2196-2204Subventions
Organisme : National Natural Science Foundation of China
ID : 82003863
Organisme : Shanghai "Rising Stars of Medical Talent" Youth Development Program Clinical Pharmacist Program
ID : SHWRS(2021)_099
Organisme : Shanghai Municipal Health Commission Special Project for Clinical Research in Health Care Industry
ID : 202040424
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Sarid N, Bokstein F, Blumenthal DT, et al. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. J Neurooncol. 2021;151(2):211-220.
Low S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord. 2018;11:1756286418793562.
Holdhoff M, Mrugala MM, Grommes C, et al. Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J Natl Compr Cancer Netw. 2020;18(11):1571-1578.
Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102(4):673-677.
Yu J, Du H, Ye X, Zhang L, Xiao H. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Sci Rep. 2021;11(1):2125.
Garcilazo-Reyes Y, Alentorn A, Duran-Pena A, Hoang-Xuan K, Houillier C. Treatment of primary central nervous system lymphoma in immunocompetent patients. Curr Treat Options Neurol. 2019;21(8):39.
Bernard S, Hachon L, Diasonama JF, et al. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. Ann Hematol. 2021;100(4):979-986.
Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-1482.
May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma. 2014;55(6):1345-1349.
Drost SA, Wentzell JR, Giguère P, et al. Outcomes associated with reducing the urine Alkalinization threshold in patients receiving high-dose methotrexate. Pharmacotherapy. J Human Pharmacol Drug Therapy. 2017;37(6):684-691.
Van der Beek JN, Oosterom N, Pieters R, de Jonge R, van den Heuvel-Eibrink MM, Heil SG. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: a systematic review. Crit Rev Oncol Hematol. 2019;142:1-8.
Peng C, Li X, Huang H, et al. A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients. Leuk Lymphoma. 2020;61(8):1842-1849.
Bergner N, Monsef I, Illerhaus G, Engert A, Skoetz N. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev. 2012;11:CD009355.
Kawakatsu S, Nikanjam M, Lin M, et al. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019;84(6):1339-1348.
Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565-571.
Al-Quteimat OM, Al-Badaineh MA. Practical issues with high dose methotrexate therapy. Saudi Pharm J. 2014;22(4):385-387.
Flombaum CD, Liu D, Yan SQ, et al. Management of Patients with acute methotrexate nephrotoxicity with high-dose Leucovorin. Pharmacotherapy. 2018;38(7):714-724.
Gokbuget N, Hoelzer D. Vindesine in the treatment of leukaemia. Leuk Lymphoma. 1997;26(5-6):497-506.
Wang Y, Wei L, Guan Y, Wang Q, Xie Q, Hao C. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients. Ren Fail. 2020;42(1):1111-1117.
Hegyi M, Gulacsi A, Csagoly E, et al. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. J Cancer Res Clin Oncol. 2012;138(10):1697-1702.
Li H, Xu Q, Wang Y, Chen K, Li J. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2020;85(1):95-103.
Huang C, Xia F, Xue L, et al. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer Chemother Pharmacol. 2020;85(2):433-441.